Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

被引：0
|
作者：
Demeter, J.
Balassa, K.
Domotor, M.
Egyed, M.
Gasztonyi, Z.
Aryab, H.
Gurzo, M.
Ivayi, J.
Klucsik, Zs.
Sreter, L.
Nagy, Zs.
机构：
[1] Semmelweis Univ, Sopron Hosp, Dept Med, Kaposvar, Hungary
[2] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary
[3] Petz Aladar Hosp Gyor, Kecskemet, Hungary
[4] Dept Med 2, Kecskemet, Hungary
[5] Markusovsky Hosp, Dept Internal Med, Szombathely, Hungary
来源：
BLOOD REVIEWS | 2007年 / 21卷
关键词：
D O I：
10.1016/S0268-960X(07)70245-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S138 / S139
页数：2
相关论文
共 50 条
  • [1] The use of Yttrium-90 -: Ibritumomab Tiuxetan in follicular lymphoma
    Dolera, T. Mut
    Bello, P.
    Olivas, C.
    Vercher, J. L.
    Asensio, I.
    Gil, H.
    Rivas, A.
    Velasco, R. P.
    Ruiz, C.
    Marti, J. F.
    Mateo, A.
    La Fe, H. U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S263 - S263
  • [2] The use of Yttrium-90 - Ibritumomab tiuxetan in follicular lymphoma
    Kolindou, A.
    Kitsou, E.
    Georgiou, A.
    Angelopoulou, M.
    Kokkori, S.
    Lafioniatis, S.
    Panagiotidis, P.
    Pangalis, G.
    Kyriaki-Manolaraki, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S263 - S264
  • [3] Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma
    Weigert, Oliver
    Illidge, Tim
    Hiddemann, Wolfgang
    Dreyling, Martin
    CANCER, 2006, 107 (04) : 686 - 695
  • [4] Long-term responses in patients with relapsed or refractory follicular lymphoma treated with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Macklis, R
    Molina, A
    Pohlman, B
    Gordon, L
    Wang, H
    Saville, MW
    Witzig, T
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S542 - S543
  • [5] Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Zimmer, AM
    SEMINARS IN NUCLEAR MEDICINE, 2004, 34 (01) : 14 - 19
  • [6] Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma
    Sanchez Ruiz, Antonio C.
    de la Cruz-Merino, Luis
    Provencio Pulla, Mariano
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (03) : 78 - 90
  • [7] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL).
    Schilder, RJ
    Witzig, TE
    Flinn, I
    Gordon, LI
    Emmanouilides, C
    Wang, H
    Vo, K
    Molina, A
    BLOOD, 2004, 104 (11) : 719A - 719A
  • [8] Consolidation with90Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma
    Miura, Katsuhiro
    Tsujimura, Hideki
    Masaki, Yasufumi
    Iino, Masaki
    Takizawa, Jun
    Maeda, Yoshinobu
    Yamamoto, Kazuhiko
    Tamura, Shinobu
    Yoshida, Akiyo
    Yagi, Hideo
    Yoshida, Isao
    Kitazume, Koichi
    Masunari, Taro
    Choi, Ilseung
    Kakinoki, Yasutaka
    Suzuki, Ritsuro
    Yoshino, Tadashi
    Nakamura, Shigeo
    Hatta, Yoshihiro
    Yoshida, Takashi
    Kanno, Masatoshi
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 51 - 59
  • [9] Yttrium-90 (Ytracis) Labelled Ibritumomab Tiuxetan (Zevalin) in Patients with Relapsed or Refractory B-Cell non-Hodkin's Lymphoma
    Lipp, R. W.
    Piswanger-Soelkner, J. C.
    Dorda, A. F.
    Brezinschek, R. I.
    Lackner, H.
    Linkesch, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S93 - S93
  • [10] Yttrium 90 ibritumomab tiuxetan in lymphoma
    Cheung, Matthew C.
    Haynes, Adam E.
    Stevens, Adrienne
    Meyer, Ralph M.
    Imrie, Kevin
    LEUKEMIA & LYMPHOMA, 2006, 47 (06) : 967 - 977
12345